ENSG vs FMS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ENSG presents a stable financial profile with a Piotroski F-Score of 5/9, indicating consistent but not exceptional operational health. While the stock trades at a significant premium to its Graham Number ($71.38), this is justified by robust 20.2% YoY revenue growth and a stellar 25-quarter earnings track record. However, the current price of $189.94 has exceeded the growth-based intrinsic value of $172.57, and bearish insider activity combined with a 0/100 technical trend suggests a period of consolidation or correction may be imminent.
FMS presents a classic deep-value opportunity, characterized by a stable Piotroski F-Score of 6/9 and a current price ($22.77) trading significantly below both its Graham Number ($35.27) and Intrinsic Value ($58.12). While top-line revenue growth is stagnant (-0.30%), the company has demonstrated a massive recovery in earnings and maintains a sustainable dividend payout ratio of 42.76%. The valuation is exceptionally attractive with a Forward P/E of 5.62 and a Price/Book of 0.81. However, the bullish value thesis is countered by a completely bearish technical trend and weak insider sentiment, suggesting a 'value trap' risk if revenue does not stabilize.
Compare Another Pair
Related Comparisons
ENSG vs FMS: Head-to-Head Comparison
This page compares The Ensign Group, Inc. (ENSG) and Fresenius Medical Care AG (FMS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.